{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:04:04Z","timestamp":1776132244087,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.jprot.2016.02.021","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T03:08:03Z","timestamp":1456456083000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["The secretome signature of malignant mesothelioma cell lines"],"prefix":"10.1016","volume":"145","author":[{"given":"Marcello","family":"Manfredi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Gosetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7600-8215","authenticated-orcid":false,"given":"Elia","family":"Ranzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Marengo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.jprot.2016.02.021_bb0005","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdq173","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Stahel","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jprot.2016.02.021_bb0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MCP.0b013e328302851d","article-title":"Malignant mesothelioma 2008","volume":"14","author":"Zervos","year":"2008","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.jprot.2016.02.021_bb0015","first-page":"189","article-title":"Lung cancer: biology and treatment options","volume":"2015","author":"Lemjabbar-Alaoui","year":"1856","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jprot.2016.02.021_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejcts.2007.09.044","article-title":"Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients","volume":"33","author":"Borasio","year":"2008","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.jprot.2016.02.021_bb0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.semtcvs.2009.07.005","article-title":"Multimodality management of malignant pleural mesothelioma: introduction","volume":"21","author":"Sugarbaker","year":"2009","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.jprot.2016.02.021_bb0030","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jprot.2016.02.021_bb0035","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ctrv.2015.05.001","article-title":"The established and future biomarkers of malignant pleural mesothelioma","volume":"41","author":"Panou","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jprot.2016.02.021_bb0040","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/pr901072h","article-title":"Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum","volume":"9","author":"Piersma","year":"2010","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jprot.2016.02.021_bb0045","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.jprot.2010.07.001","article-title":"Secretome proteomics for discovery of cancer biomarkers","volume":"73","author":"Makridakis","year":"2010","journal-title":"J. Proteome"},{"key":"10.1016\/j.jprot.2016.02.021_bb0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jprot.2014.03.007","article-title":"SWATH- and iTRAQ-based quantitative proteomic analyses reveal an overexpression and biological relevance of CD109 in advanced NSCLC","volume":"102","author":"Zhang","year":"2014","journal-title":"J. Proteome"},{"key":"10.1016\/j.jprot.2016.02.021_bb0055","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/jcb.22316","article-title":"Spreading of mesothelioma cells is rapamycin-sensitive and requires continuing translation","volume":"108","author":"Ranzato","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jprot.2016.02.021_bb0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1074\/mcp.M113.030775","article-title":"Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma","volume":"13","author":"Mundt","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.jprot.2016.02.021_bb0065","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jprot.2011.09.026","article-title":"Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker","volume":"75","author":"Hosako","year":"2012","journal-title":"J. Proteome"},{"key":"10.1016\/j.jprot.2016.02.021_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2016.02.021_bb0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2011.07.009","article-title":"Proteomic surfaceome analysis of mesothelioma","volume":"75","author":"Ziegler","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jprot.2016.02.021_bb0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1559-0275-10-16","article-title":"Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring","volume":"10","author":"Cerciello","year":"2013","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.jprot.2016.02.021_bb0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature01511","article-title":"Mass spectrometry-based proteomics","volume":"422","author":"Aebersold","year":"2003","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.jprot.2016.02.021_bb0090","article-title":"N-glycoproteome analysis of the secretome of human metastatic hepatocellular carcinoma cell lines combining hydrazide chemistry, HILIC enrichment and mass spectrometry","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2016.02.021_bb0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cbpa.2008.07.024","article-title":"Mass spectrometry for proteomics","volume":"12","author":"Han","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jprot.2016.02.021_bb0100","series-title":"IEEE International Symposium on Medical Measurements and Applications, MeMeA 2015 \u2014 Proceedings","first-page":"526","article-title":"Targeted quantitation of HMGB1 protein by label-free mass spectrometry technique","author":"Manfredi","year":"2015"},{"key":"10.1016\/j.jprot.2016.02.021_bb0105","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.O111.016717","article-title":"Targeted data extraction of the MS\/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis","volume":"11","author":"Gillet","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.jprot.2016.02.021_bb0110","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s00216-011-5641-8","article-title":"High-resolution mass spectrometry for integrated qualitative and quantitative analysis of pharmaceuticals in biological matrices","volume":"402","author":"Hopfgartner","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jprot.2016.02.021_bb0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.taap.2013.10.025","article-title":"Combination of ascorbate\/epigallocatechin-3-gallate\/gemcitabine synergistically induces cell cycle deregulation and apoptosis in mesothelioma cells","volume":"274","author":"Martinotti","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jprot.2016.02.021_bb0120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1165\/rcmb.2009-0340OC","article-title":"Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism","volume":"44","author":"Ranzato","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jprot.2016.02.021_bb0125","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.jprot.2016.02.021_bb0130","first-page":"235","article-title":"The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance","volume":"121","author":"Blobel","year":"1985","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jprot.2016.02.021_bb0135","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/ncponc1187","article-title":"Strategies for discovering novel cancer biomarkers through utilization of emerging technologies","volume":"5","author":"Kulasingam","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.jprot.2016.02.021_bb0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ajco.12306","article-title":"Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care","volume":"11","author":"Kao","year":"2015","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.jprot.2016.02.021_bb0145","first-page":"3080","article-title":"Gene expression profiling of malignant mesothelioma","volume":"9","author":"Singhal","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jprot.2016.02.021_bb0150","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/pros.22581","article-title":"Dystroglycan function is a novel determinant of tumor growth and behavior in prostate cancer","volume":"73","author":"Mitchell","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.jprot.2016.02.021_bb0155","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.1038\/ncomms7184","article-title":"An oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinoma","volume":"6","author":"Chakraborty","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jprot.2016.02.021_bb0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1476-4598-13-65","article-title":"Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma","volume":"13","author":"Song","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jprot.2016.02.021_bb0165","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0002-9440(10)63739-X","article-title":"Proteomic analysis of exosomes secreted by human mesothelioma cells","volume":"164","author":"Hegmans","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jprot.2016.02.021_bb0170","first-page":"153","article-title":"Expression of the ERM family members (ezrin, radixin and moesin) in breast cancer","volume":"1","author":"Fernando","year":"2010","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.jprot.2016.02.021_bb0175","doi-asserted-by":"crossref","first-page":"137R","DOI":"10.1093\/glycob\/cwl025","article-title":"Galectin-1: a small protein with major functions","volume":"16","author":"Camby","year":"2006","journal-title":"Glycobiology"},{"key":"10.1016\/j.jprot.2016.02.021_bb0180","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1158\/0008-5472.CAN-12-0326","article-title":"Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis","volume":"73","author":"Yokobori","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jprot.2016.02.021_bb0185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/138161213804143725","article-title":"The therapeutic target Hsp90 and cancer hallmarks","volume":"19","author":"Miyata","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jprot.2016.02.021_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0065-2660(10)69006-2","article-title":"GRP78 signaling hub a receptor for targeted tumor therapy","volume":"69","author":"Sato","year":"2010","journal-title":"Adv. Genet."}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391916300434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391916300434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T03:18:05Z","timestamp":1542943085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391916300434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":38,"alternative-id":["S1874391916300434"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2016.02.021","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The secretome signature of malignant mesothelioma cell lines","name":"articletitle","label":"Article Title"},{"value":"Journal of Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jprot.2016.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}